Analysis of U.S. Patent 4,358,449: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 4,358,449?
U.S. Patent 4,358,449, granted on November 9, 1982, covers a class of synthetic compounds primarily designed as pharmaceutical agents. The patent's scope focuses on imidazoline derivatives used as antihypertensives and central nervous system modulators. Its claims center on specific chemical structures, methods of synthesis, and their pharmaceutical applications.
The patent claims encompass both the chemical structures and their methods of preparation, emphasizing compounds with a formula involving a benzyl or alkyl substituent attached to an imidazoline core. The scope extends to pharmaceutical compositions containing these compounds and their use in reducing blood pressure or acting on CNS receptors.
Core Structural Features Included:
- Imidazoline rings with various substitutions.
- Aromatic groups, such as phenyl.
- Alkyl chains attached to nitrogen atoms within the imidazoline core.
The scope does not broadly extend beyond the specified chemical classes, avoiding genus claims that cover entire families outside the defined substituents.
What are the Key Claims in U.S. Patent 4,358,449?
The patent contains 11 claims, with distinctions between independent and dependent claims. The primary claim (Claim 1) defines a chemical compound with a structure characterized by:
- An imidazoline ring.
- Specific substituents on nitrogen and carbon atoms.
- Possible aromatic or alkyl groups attached.
Claim 1 (primary claim):
A compound of the formula:
[Chemical structure depicted],
wherein R₁ is phenyl, benzyl, or alkyl groups; R₂ is hydrogen or alkyl; and R₃ is hydrogen or halogen.
Subsequent dependent claims specify particular substituents, such as 6-(2-thienyl)imidazoline derivatives or compounds with specific methyl or chloro groups.
Method claims include:
- Methods of synthesizing these compounds through alkylation and cyclization steps.
- Use claims cover pharmaceutical formulations containing these compounds for treating hypertension or related conditions.
Patent Landscape and Related Patents
Overlapping Patents and Prior Art
- The patent overlaps with prior art related to imidazoline-based antihypertensives, such as clonidine patents.
- Similar compounds with imidazoline core structures have been patented in the 1970s and early 1980s, creating a patent cluster around central imidazoline pharmacophores for blood pressure management.
- The patent’s claims may be challenged or limited by prior art, especially given the activity of clonidine and derivatives disclosed before 1982.
Patent Litigation and Litigation Risk
- The patent’s claims have not been litigated extensively but face potential challenges based on earlier disclosures.
- Broad claims covering "imidazoline derivatives" are vulnerable to invalidity defenses if prior art demonstrates the compounds are obvious.
Patent Status and Lifecycle
- The patent has expired, as it was filed in 1980 and granted in 1982, with a 20-year term ending in 2002.
- Expiration opens the landscape for generic development and further research.
Comparative Overview of Similar Patents
| Patent Number |
Filing Year |
Main Claims |
Key Compounds |
Status |
| US 4,245,052 |
1980 |
Imidazoline derivatives as antihypertensives |
Similar imidazoline compounds |
Expired |
| EP 0,006,703 |
1981 |
Imidazoline compounds for CNS activity |
Variations of imidazoline core |
Expired |
Implications for Current Research and Development
While the patent expired, its foundational claims influence subsequent inventiveness in imidazoline derivatives. Researchers developing new compounds must design around the original claims, focusing on novel substitutions or improved pharmacokinetics.
Key Takeaways
- U.S. Patent 4,358,449 had a scope limited to specific imidazoline derivatives for blood pressure regulation.
- Its claims focused on chemical structures and synthesis methods, with broad yet specific coverage.
- The patent landscape around imidazoline compounds included overlapping prior art, primarily involving antihypertensive agents like clonidine.
- Expiration in 2002 allows free use of the covered compounds, spurring generic and research activity.
- New developments should avoid prior structures or improve upon the claims’ limitations to establish non-infringing alternatives.
FAQs
1. What is the primary therapeutic application covered by U.S. Patent 4,358,449?
It relates to compounds used as antihypertensive agents.
2. Does the patent cover all imidazoline derivatives?
No, it covers specific derivatives defined by particular substituents within the claims.
3. Are the compounds covered by this patent still under patent protection?
No, the patent expired in 2002.
4. Can new drugs be developed based on these compounds without licensing?
Yes, since the patent expired, novel derivatives must still consider literature and prior art to avoid infringement.
5. How does the patent landscape impact current research?
It guides innovators to design around the original claims or improve upon them, considering prior art and expired patent protections.
References
- United States Patent and Trademark Office. (1982). U.S. Patent No. 4,358,449.
- Gennaro, R. (Ed.). (2010). Remington: The Science and Practice of Pharmacy. 21st Edition. Pharmaceutical knowledge applicable to the patent.
